Novartis has announced that its treatment, Lutathera, has received approval from the U.S. Food and Drug Administration to treat pediatric patients aged 12 and older. The treatment is specifically for those with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, which include foregut, midgut, and hindgut neuroendocrine tumors.
Gastroenteropancreatic neuroendocrine tumors are a rare cancer that are often unable to be surgically removed and are usually diagnosed at advanced stages.
Lutathera has also received approval in Europe for dealing with unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. In Japan, it has been approved for treating somatostatin receptor-positive neuroendocrine tumors.
Novartis also noted that they are conducting further research into radioligand therapies to treat a broad range of cancers, including gastroenteropancreatic neuroendocrine tumors, as well as lung, prostate, breast, colon, brain and pancreatic cancers.
For more health-related news, visit rttnews.com.
